Pharma major Lupin on Monday said it has launched its Sildenafil tablets used for the treatment of erectile dysfunction in the US market. The company has launched Sildenafil tablets USP in the strengths of 25 mg, 50 mg and 100 mg after receiving approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a filing to the BSE. The company's product is the generic version of Pfizer Inc's Viagra tablets in the same strengths, it added. As per IQVIA MAT July 2019 data, Sildenafil tablets USP, 25 mg, 50 mg, and 100 mg had total annual sales of around USD 216 million in the US, Lupin said. Sildenafil tablets are indicated for the treatment of erectile dysfunction, it added. Shares of Lupin Ltd on Monday closed at Rs 715.85 per scrip on the BSE, down 0.09 per cent from its previous close. AKT HRS
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!